Trial · NCT01392183
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 158
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Temsirolimus (Control Group) | 4 | 50 | 5 |
| other | Abdominal Pain | Gastrointestinal disorders | Pazopanib (Treatment Group) | 8 | 55 | 12 |
| other | ALT Increased | Hepatobiliary disorders | Temsirolimus (Control Group) | 3 | 50 | |
| other | ALT Increased | Hepatobiliary disorders | Pazopanib (Treatment Group) | 19 | 55 | 47 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Temsirolimus (Control Group) | 8 | 50 | 10 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Pazopanib (Treatment Group) | 9 | 55 | 17 |
| other | Alk Phos Increased | Hepatobiliary disorders | Temsirolimus (Control Group) | 15 | 50 | 27 |
| other | Alk Phos Increased | Hepatobiliary disorders | Pazopanib (Treatment Group) | 17 | 55 | 35 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Temsirolimus (Control Group) | 2 | 50 | 2 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Pazopanib (Treatment Group) | 5 | 55 | 8 |
| other | Anemia | Blood and lymphatic system disorders | Temsirolimus (Control Group) | 31 | 50 | 112 |
| other | Anemia | Blood and lymphatic system disorders | Pazopanib (Treatment Group) | 8 | 55 | 18 |
| other | Anorexia | Gastrointestinal disorders | Temsirolimus (Control Group) | 9 | 50 | 15 |
| other | Anorexia | Gastrointestinal disorders | Pazopanib (Treatment Group) | 18 | 55 | 25 |
| other | AST increased | Hepatobiliary disorders | Temsirolimus (Control Group) | 9 | 50 | 12 |
| other | AST increased | Hepatobiliary disorders | Pazopanib (Treatment Group) | 19 | 55 | 53 |
| other | Chest Wall Pain | Musculoskeletal and connective tissue disorders | Temsirolimus (Control Group) | 2 | 50 | 3 |
| other | Chest Wall Pain | Musculoskeletal and connective tissue disorders | Pazopanib (Treatment Group) | 4 | 55 | 6 |
| other | Chholesterol high | Metabolism and nutrition disorders | Temsirolimus (Control Group) | 4 | 50 | 31 |
| other | Chholesterol high | Metabolism and nutrition disorders | Pazopanib (Treatment Group) | 1 | 55 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01392183/events